City
Epaper

Administration of ZyCoV-D vaccine requires special training; awaiting NTAGI's final advice: Dr VK Paul

By ANI | Published: October 21, 2021 10:04 AM

Zydus Cadila's vaccine - ZyCoV-D is the first indigenously manufactured needle-free Covid-19 vaccine which is approved for children aged above 12 for emergency use in the country. Earlier, the Subject Experts Committee (SEC) has also recommended the Hyderabad-based Bharat Biotech's Covaxin for emergency use in Children.

Open in App

Zydus Cadila's vaccine - ZyCoV-D is the first indigenously manufactured needle-free Covid-19 vaccine which is approved for children aged above 12 for emergency use in the country. Earlier, the Subject Experts Committee (SEC) has also recommended the Hyderabad-based Bharat Biotech's Covaxin for emergency use in Children.

In an exclusive interview with ANI, Dr VK Paul, Member(Health), Niti Aayog said the ZyCoV-D vaccine administration requires special training.

"So it is a vaccine and is known by the name ZyCoV-D, the DNA vaccine, which is a three-dose vaccine. It is now licenced for children ages above 12 years. It is an extremely safe, homegrown vaccine made with funding from the DBT etc. So it's a very special vaccine. This is an achievement of India and the industry is very proud of this vaccine," said Dr Paul.

Further explaining the ZyCoV-D vaccine application, he said, "As you know, this is a slightly different vaccine in the sense that it is not given through a syringe or needle. It is given through an applicator or a jet that impinges on the skin and the vaccine gets deposited just below the skin."

Talking about its doses he said, "Two doses are given as the first dose and then you repeat and repeat. So it's somewhat different and the important aspect is training, which is important for the team, state-level and sub-state level, that is one. Secondly, use an applicator and not a syringe. Provision and training to use the application are going on."

Giving insights on its current situation and how to incorporate it into the national programme," Dr Paul said, "We are waiting for National Technical Advisory Group on immunizations (NTAGI) final advice on what is the best use of the stockpile, that is available to us to the tune of about three crore doses."

"What is the best way to use it, should we use it for children. Should we use it for adults? They know the technicality, scientific speciality specific characteristics of this vaccine. We look forward to the decision, work is in progress, but we are, we are moving forward for incorporating this vaccine into our national programme," he added.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Subject experts committeeBharat biotechNiti AayogBharat biotech limitedNational mission for sustainable agricultureBharat biotech international ltdBharat biotech companyNiti aayog atal innovation missionNational institution for transforming indiaNational skill development council of indiaBharat biotech biotech
Open in App

Related Stories

NationalCovaxin-Developer Bharat Biotech Amid Reports on AstraZeneca Vaccine, Says ‘Safety Is Primary Focus for All Our Vaccines’

BusinessIndia’s Poverty Level Has Fallen Below 5%, Says NITI Aayog CEO BVR Subrahmanyam

MaharashtraAgriculture Policy Expert Dr Shashank Kulkarni from Sangli Selected as Agriculture Advisor to NITI Aayog

InternationalIssues regarding OCI cards in Reunion Island resolved: PM Modi

TechnologyOPPO India joins Atal Innovation Mission to set up 1st PPP-model Atal Tinkering Lab

National Realted Stories

NationalBJP, Cong spar on fuel prices in states ruled by them

NationalWest Bengal Train Accident: Mamata Banerjee Slams Central Govt, Says “Railway Ministry Exists Only in Name Now"

NationalTop Congress Leaders Meet to Decide Rahul Gandhi's Lok Sabha Seat: Reports

NationalConditions favourable for monsoon to advance further: IMD

NationalBengal train accident: Saha announces Rs 2 lakh ex-gratia to kin of victims from Tripura, if any